Deep Dive

Industry insights from our journalists


  • A picture of the street sign stating "Wall Street." American flags drape over a nearby building
    Image attribution tooltip
    Kena Betancur via Getty Images

    Health tech companies weigh funding options amid weak IPO market

    Healthcare technology companies are delaying initial share sales and searching for new sources of cash. Experts don’t expect a quick recovery.

    Sydney Halleman • Nov. 21, 2022
  • A person sits on the edge of a couch looking out a window in a living room setting.
    Image attribution tooltip

    Photo: Amanda Greene for Industry Dive

    ‘I don’t feel safe.’ Abortion bans add new uncertainty to fertility treatment

    BioPharma Dive’s Delilah Alvarado worked with reporters from Healthcare Dive to examine the impact of state laws banning abortion on people trying to conceive via in vitro fertilization.

    Sydney Halleman, Delilah Alvarado, Shaun Lucas and Jasmine Ye Han • Oct. 24, 2022
  • Image attribution tooltip
    Jeff J Mitchell via Getty Images

    Can biosimilars, after years of limited impact, finally make a mark in the US?

    Seven years after the first copycat biologic drug arrived in the U.S., expected cost savings have been modest at best. The next few years will show whether the knockoff drugs can live up to their cut-price promise.

    Jonathan Gardner • Sept. 7, 2022
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    MadamLead via Getty Images

    'Flat is the new up': After biotech correction, venture investors turn to safer bets

    New companies are being built more carefully and platform technologies are less in vouge as the downturn's effects ripple through the private sector.

    Ben Fidler • July 26, 2022
  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive

    10 clinical trials to watch in the second half of 2022

    The biotech industry's downturn accelerated in the first half of the year. Important study readouts for Eisai, Gilead, Merck and Seagen, among others, could determine whether the slump endures.

    Ben Fidler, Ned Pagliarulo and Jacob Bell • July 5, 2022
  • A child plays EndeavorRx on a tablet. The digital therapeutic intended to improve attention in kids with ADHD.
    Image attribution tooltip
    Permission granted by Akili Interactive

    Can digital therapeutics be profitable?

    Licensing deals with pharmaceutical companies were an early strategy for digital health companies, but not all of them have lasted.

    Elise Reuter • April 11, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    How a long shot ALS drug came before the FDA

    A negative vote from independent experts appears to lower the chances of Amylyx's medicine winning FDA approval. Still, FDA officials have cited flexibility and noted the difficulty of its forthcoming decision. 

    Jacob Bell • March 28, 2022
  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip
    AbbVie

    Two decades and $200 billion: AbbVie's Humira monopoly nears its end

    Biosimilar copies of Humira will arrive in the U.S. beginning early next year, testing both AbbVie and the market potential for knockoff biologic drugs.

    Jonathan Gardner • March 17, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images

    'The music stopped': Biotech rout leaves drug startups grounded as demand slumps for IPOs

    For the first time in years, biotechs no longer have an easy path onto Wall Street, a market reversal that could change what the next generation of young drugmakers looks like.

    Ben Fidler • Feb. 7, 2022
  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive

    10 clinical trials to watch in the first half of 2022

    Biotech stocks ended 2021 in a slump. But positive results from eagerly anticipated studies in breast cancer, schizophrenia and Alzheimer's disease could help turn the sector's fortunes around.

    Ben Fidler • Updated Jan. 6, 2022
  • Cedars-Sinai lab technicians conduct ALS research.
    Image attribution tooltip
    Permission granted by The ALS Association

    On the hunt for new ALS drugs, researchers see progress, and a long road ahead

    The fatal nerve disease has few treatments. But despite continued setbacks, drug developers are hopeful that genetic technologies and a better understanding of biology will bring new options in the not-too-distant future

    Jacob Bell • Dec. 13, 2021
  • A photo of Sekar Kathiresan, CEO of Verve Therapeutics
    Image attribution tooltip
    Seth Babin/BioPharma Dive

    Heart attacks struck Sek Kathiresan's family. He's devoted his life to stopping them.

    After several family members had early heart attacks, Kathiresan vowed to understand why they happen. His research journey has changed medical practice and led to a new biotech startup, Verve Therapeutics, that seeks to prevent them.

    Ben Fidler • Nov. 29, 2021
  • Dr. Jason Comander performs the first Luxturna surgery post-FDA approval on March 20, 2018 at Massachusetts Eye and Ear.
    Image attribution tooltip
    Permission granted by Ed Shipman for Mass Eye and Ear

    Years later, a first-of-its-kind treatment shows the power, and limits, of gene therapy

    Luxturna, approved four years ago as the first gene therapy for an inherited disease in the U.S., is improving sight and quality of life for several of the patients who received it.

    Shoshana Dubnow • Nov. 15, 2021
  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive

    A three-decade monopoly: how Amgen built a patent thicket around its top-selling drug

    Through high-stakes litigation, aggressive patenting practices and a bit of luck, Amgen will likely stretch Enbrel's monopoly until 2029, more than 30 years after it was approved.

    Jonathan Gardner • Nov. 1, 2021
  • Image attribution tooltip
    Justin Sullivan via Getty Images

    A play-by-play of the FDA's meeting on Pfizer's vaccine for kids

    Experts on the agency's panel dug into questions on the vaccine's safety in younger children, as well as uncertainty over how widely it should be used. Catch up on the discussion here. 

    Ben Fidler, Shoshana Dubnow and Jonathan Gardner • Updated Oct. 26, 2021
  • Vertex CEO Reshma Kewalramani
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals

    'This is the time to double down': Top Vertex executives defend research plan as pressure builds

    A series of setbacks has led to criticism of the storied biotech's bid to diversify. But Vertex intends to stay the course, its CEO and top scientist say.

    Ben Fidler • Sept. 22, 2021
  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive

    Biotech M&A is picking back up. Here are the latest deals.

    AstraZeneca’s acquisition of Neogene is its third biotech buyout this year, expanding its capabilities in cell therapy, gene editing and bispecific antibodies.

    Jacob Bell and Julia Himmel • Updated Nov. 29, 2022
  • An illustration of CRISPR-cas9 gene editing
    Image attribution tooltip
    del Aguila III, Ernesto. (2018). "CRISPR Cas9" [Illustration]. Retrieved from Flickr.

    Intellia, with first results, delivers a 'landmark' for CRISPR gene editing

    Results published in The New England Journal of Medicine offer the first clinical evidence that CRISPR gene editing inside the body can be safe and effective, a culmination of years of scientific research.  

    Ben Fidler • June 26, 2021
  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive

    8 key clinical trials to watch for the rest of 2021

    The next six months could feature clinical milestones for CRISPR gene editing, the treatment of COVID-19 and gene-targeted cancer therapy.

    Ben Fidler • June 21, 2021
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive

    'The lights are no longer green': Antitrust regulators reassess pharma deals

    The FTC and its counterparts abroad are rethinking their approach to drugmaker acquisitions. Past scrutiny offers clues to where they may look next.

    Jonathan Gardner • June 10, 2021
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen

    A first-of-its-kind Alzheimer's drug raises heavy questions around who will and won't get it

    Biogen priced its newly approved medicine Aduhelm at an average cost of $56,000 a year, adding affordability to other barriers patients may face. 

    Jacob Bell • June 8, 2021
  • Ajay Purohit, a Biogen employee, points to brain scans of people with Alzheimer's
    Image attribution tooltip
    Permission granted by Biogen

    In historic move, FDA approves a closely watched and controversial Alzheimer's drug

    The decision cleared the way for what many predicted would become a lucrative treatment. But a high price and controversy over whether Biogen's Aduhelm benefits patients weighed heavily on the drug's launch.

    Jacob Bell • Updated June 7, 2021
  • A picture of the street sign stating "Wall Street." American flags drape over a nearby building
    Image attribution tooltip
    Kena Betancur via Getty Images

    Trump tax law cut what US drugmakers owed. Now they fear an increase.

    The 2017 law saved pharmaceutical companies billions of dollars, BioPharma Dive found. Executives are now fiercely opposing tax hikes proposed by President Biden, claiming they've since boosted domestic investment. 

    Jonathan Gardner • May 17, 2021
  • A sign at Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences

    How Gilead finally spent its money

    This year, the biotech spent about $27 billion trying to become a leader in cancer research. Executives who spoke to BioPharma Dive said there's still work to be done.

    Jacob Bell • Nov. 24, 2020
  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive

    After a record run, fewer biotechs are going public. Here’s how they’re performing.

    Just 20 drugmakers have priced an initial public offering this year, less than one-fifth last year’s total of 104, according to BioPharma Dive data.

    Ben Fidler • Updated Nov. 18, 2022